Overview: PML RARA t(15;17) Quantitative MRD TestIntroduction: The PML RARA t(15;17) Quantitative MRD Test quantifies PML-RARA to monitor leukemia relapse, aiding treatment planning. Following 2023 ASCO guidelines, it uses PCR for high specificity, supporting cancer screening. This test is critical for guiding minimal residual disease (MRD) monitoring, treatment adjustments, and improving outcomes in molecular pathology for patients with acute promyelocytic leukemia (APL).
Other Names: PML-RARA MRD Assay, Quantitative Leukemia Monitoring Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: PML-RARA testing began in the 1990s with APL research. Quantitative PCR methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Quantifies PML-RARA to monitor leukemia relapse, guides treatment, and evaluates patients with APL.
Test Parameters: 1. PML-RARA t(15;17) Quantitative
Pretest Condition: No fasting required. Collect whole blood or bone marrow. Report history of leukemia or treatment response.
Specimen: Whole Blood (EDTA, 2-5 mL), Bone Marrow (EDTA, 2-5 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document leukemia diagnosis, treatment history, or relapse symptoms. Include current medications, especially ATRA or arsenic trioxide.
Consent: Written consent required, detailing the tests purpose, leukemia relapse implications, and risks of sample collection.
Procedural Considerations: Uses quantitative PCR to measure PML-RARA t(15;17) levels. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for APL MRD monitoring.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Detectable PML-RARA indicates MRD, guiding intensified therapy or transplant. Undetectable levels suggest remission, requiring ongoing monitoring.
Specialist Consultation: Consult an oncologist or hematologist for result interpretation and treatment planning.
Additional Supporting Tests: Bone marrow cytology, FISH, or flow cytometry to confirm APL relapse.
Test Limitations: Sensitivity depends on sample quality; clinical correlation is needed. Not all APL cases are PML-RARA positive.
References: ASCO Leukemia Guidelines, 2023; Blood, Lo-Coco F, 2022.
